IASLC World Conference on Lung Cancer

Conference Coverage

Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer

09/05/2024

According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...

According to updated results...

09/05/2024

Oncology

Videos

Antitumor Activity of Amivantamab Among Patients With METex14 Non-Small Cell Lung Cancer

09/13/2023

Featuring Alexander Spira, MD, PhD

Featuring Alexander Spira, MD, PhD ...

Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.

Alexander Spira, MD, PhD,...

09/13/2023

Oncology

Videos

Amivantamab, Lazertinib, and Chemotherapy Quadruplet Therapy Demonstrated Durable Response Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/13/2023

Featuring Alexander Spira, MD, PhD

Featuring Alexander Spira, MD, PhD ...

Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...

Alexander Spira, MD, PhD,...

09/13/2023

Oncology

Videos

Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy Did Not Adversely Affect Surgical Outcomes Among Patients With Resectable Non-Small Cell Lung Cancer

09/12/2023

Featuring Tetsuya Mitsudomi, MD, PhD

Featuring Tetsuya Mitsudomi, MD, PhD ...

At the 2023 World Conference on Lung Cancer, Tetsuya Mitsudomi, MD, PhD, presented results which demonstrated the addition of perioperative durvalumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes among patients with...

At the 2023 World Conference on...

09/12/2023

Oncology

Conference Coverage

Toripalimab With First-Line Chemotherapy Yields Superiority in Advanced NSCLC

09/13/2021

Data from the CHOICE-01 phase 3 trial confirm that toripalimab in combination with first-line chemotherapy showed superior PFS, ORR, and DOR, with a manageable safety profile in patients with advanced NSCLC.

Data from the CHOICE-01 phase 3...

09/13/2021

Oncology

Conference Coverage

Camrelizumab Plus Apatinib Yields Promising Activity in Advanced NSCLC

09/13/2021

Results of a phase 2 trial reveal promising clinical activity for camrelizumab plus apatinib as a combination treatment in the frontline setting for patients with non-squamous NSCLC at the virtual 2021 World Conference on Lung Cancer.

Results of a phase 2 trial...

09/13/2021

Oncology

Videos

Dr Spira Highlights Amivantamab as Promising Treatment in METex14 Mutated NSCLC

09/10/2021

Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...

Alexander Spira, MD, PhD, FACP,...

09/10/2021

Oncology

Conference Coverage

Greater Immune Protection Against SARS-CoV-2 Needed in Lung Cancer Therapy

09/10/2021

An ongoing cohort study found that although most lung cancer patients have displayed promising antibody responses to SARS-CoV-2 vaccinations, a subgroup exhibited significantly lower antibody/neutralizing levels, indicating further studies...

An ongoing cohort study found...

09/10/2021

Oncology

Conference Coverage

Real-World Data Shows Lurbinectedin Beneficial for Pretreated SCLC and Mesothelioma

09/10/2021

Lurbinectedin offers clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma, according to real-world data presented at the 2021 IASLC World Conference on Lung Cancer.

Lurbinectedin offers clinical...

09/10/2021

Oncology

IASLC World Conference on Lung Cancer

Tracks

Specialties

Events

Year Round Education

HMP Global Products